ArticleBMC pregnancy and childbirth2026
Association of mid-to-late pregnancy 25-hydroxyvitamin D levels with hypertensive disorders in pregnancy: a BMI-stratified prospective cohort study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertensive disorders of pregnancy (HDP) are common complications that can lead to adverse maternal and fetal outcomes. Vitamin D is a fat-soluble vitamin with anti-inflammatory and vasoprotective properties that may influence the development of HDP. Body mass index (BMI) could potentially modify this association; however, studies investigating this relationship using BMI stratification remain limited.
objectiveTo investigate the association between serum 25-hydroxyvitamin D levels in mid-late pregnancy and HDP, and to analyze its predictive value based on pre-pregnancy BMI stratification.
methodsA total of 168 pregnant women from a tertiary hospital obstetric clinic between January 1, 2023, and September 30, 2024, were enrolled and stratified into normal weight group (84 cases), overweight group (50 cases), and obese group (34 cases) based on pre-pregnancy BMI. All participants underwent serum 25-hydroxyvitamin D measurement, blood pressure assessment, weight and height evaluation, and were followed up until delivery to record pregnancy outcomes.
resultsComparison of baseline characteristics revealed significant differences in pre-pregnancy BMI, systolic blood pressure, diastolic blood pressure, 24-h urine protein, total cholesterol, triglycerides, and vitamin D supplement use among groups (F = 35.624, P < 0.001; χ2 = 9.873, P = 0.007), while no significant differences were observed in age, gestational week, and parity (F = 1.624, P = 0.201; χ2 = 1.873, P = 0.392). Serum 25(OH)D levels showed significant differences among groups (F = 18.934, P < 0.001). The total incidence of HDP and preeclampsia incidence demonstrated significant differences among groups (χ2 = 11.583, P = 0.003; χ2 = 8.924, P = 0.012), whereas the incidence of gestational hypertension showed no significant difference (χ2 = 4.237, P = 0.120). Multivariate logistic regression analysis indicated that decreased 25(OH)D levels (per 5 ng/mL) were associated with increased HDP risk (Wald = 7.234, P = 0.007), while obesity (Wald = 8.362, P = 0.004), overweight (Wald = 5.102, P = 0.024), and elevated systolic blood pressure (Wald = 13.362, P < 0.001) were associated with increased risk, and vitamin D supplement use was associated with reduced risk (Wald = 6.432, P = 0.011). The area under the curve (AUC) for serum 25(OH)D in predicting HDP was 0.768, with the highest AUC in the obese group (0.808).
conclusionSerum 25-hydroxyvitamin D levels in mid-late pregnancy are negatively associated with HDP risk, and vitamin D supplement use was associated with lower risk. Exploratory BMI-stratified analyses suggested a numerically strongest association and predictive value in obese women. However, the small sample size and event count in this subgroup resulted in wide confidence intervals, high risk of overfitting, and unstable estimates, necessitating extreme caution in interpretation and mandating external validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.